Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

Abhishek Maiti; Jorge E. Cortes; Yolanda D. Brown; Hagop M. Kantarjian

doi:10.1080/10428194.2016.1207767

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

Abhishek Maiti, Jorge E. Cortes, Yolanda D. Brown, Hagop M. Kantarjian

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	722-725
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	58
Issue number	3
DOIs	https://doi.org/10.1080/10428194.2016.1207767
State	Published - Mar 4 2017
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2016.1207767

Cite this

@article{a62265deb07342dc87b360d21a76b850,

title = "Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors",

author = "Abhishek Maiti and Cortes, {Jorge E.} and Brown, {Yolanda D.} and Kantarjian, {Hagop M.}",

note = "Funding Information: This study was sponsored in part by Celgene, and by the MD Anderson Cancer Center Support Grant CA016672 (PI: Dr. Ronald DePinho) and Award Number P01 CA049639 (PI: Dr. Richard Champlin) from the National Cancer Institute.",

year = "2017",

month = mar,

day = "4",

doi = "10.1080/10428194.2016.1207767",

language = "English (US)",

volume = "58",

pages = "722--725",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

AU - Maiti, Abhishek

AU - Cortes, Jorge E.

AU - Brown, Yolanda D.

AU - Kantarjian, Hagop M.

N1 - Funding Information: This study was sponsored in part by Celgene, and by the MD Anderson Cancer Center Support Grant CA016672 (PI: Dr. Ronald DePinho) and Award Number P01 CA049639 (PI: Dr. Richard Champlin) from the National Cancer Institute.

PY - 2017/3/4

Y1 - 2017/3/4

UR - http://www.scopus.com/inward/record.url?scp=84988672721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988672721&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1207767

DO - 10.1080/10428194.2016.1207767

M3 - Letter

C2 - 27658536

AN - SCOPUS:84988672721

SN - 1042-8194

VL - 58

SP - 722

EP - 725

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this